[go: up one dir, main page]

EA200200284A1 - Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента женских контрацептивов - Google Patents

Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента женских контрацептивов

Info

Publication number
EA200200284A1
EA200200284A1 EA200200284A EA200200284A EA200200284A1 EA 200200284 A1 EA200200284 A1 EA 200200284A1 EA 200200284 A EA200200284 A EA 200200284A EA 200200284 A EA200200284 A EA 200200284A EA 200200284 A1 EA200200284 A1 EA 200200284A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mesoprogestins
progesterone receptor
contraception
mesoprogestines
contraceptives
Prior art date
Application number
EA200200284A
Other languages
English (en)
Other versions
EA006805B1 (ru
Inventor
Кристоф Хвализц
Вальтер Эльгер
Герд Шуберт
Original Assignee
Йенафарм Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йенафарм Гмбх Унд Ко. Кг filed Critical Йенафарм Гмбх Унд Ко. Кг
Publication of EA200200284A1 publication Critical patent/EA200200284A1/ru
Publication of EA006805B1 publication Critical patent/EA006805B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описано применение мезопрогестинов для приготовления фармацевтического средства, предназначенного для женской контрацепции, фармацевтическая композиция, предназначенная для женской контрацепции, и способ осуществления женской контрацепции, предусматривающий введение эффективных количеств мезопрогестина женщине, нуждающейся в контрацепции. Мезопрогестин необязательно можно применять в сочетании с эстрогеном. Мезопрогестины в контексте настоящего описания определяются как соединения, обладающие как агонистической, так и антагонистической активностями в отношении рецептора прогестерона (PR) in vivo. Они стабилизируют функцию PR на уровне, который является промежуточным между агонистическим и антагонистическим уровнем. Соответствующие функциональные состояния не могут быть достигнуты с помощью прогестинов или антипрогестинов. Предпочтительными мезопрогестинами по изобретению являются J 867, J 912, J 956 и J 1042.Отчет о международном поиске был опубликован 2002.01.17.
EA200200284A 1999-08-31 2000-08-31 Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента женских контрацептивов EA006805B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31
PCT/IB2000/002053 WO2001026603A2 (en) 1999-08-31 2000-08-31 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives

Publications (2)

Publication Number Publication Date
EA200200284A1 true EA200200284A1 (ru) 2002-10-31
EA006805B1 EA006805B1 (ru) 2006-04-28

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200284A EA006805B1 (ru) 1999-08-31 2000-08-31 Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента женских контрацептивов

Country Status (28)

Country Link
EP (1) EP1605949A2 (ru)
JP (1) JP2003511399A (ru)
KR (1) KR20020038745A (ru)
CN (1) CN1384748A (ru)
AR (1) AR025455A1 (ru)
AU (1) AU781835B2 (ru)
BG (1) BG106441A (ru)
BR (1) BR0013711A (ru)
CA (1) CA2383650A1 (ru)
CO (1) CO5190694A1 (ru)
CZ (1) CZ2002707A3 (ru)
EA (1) EA006805B1 (ru)
EE (1) EE200200103A (ru)
HR (1) HRP20020265A2 (ru)
HU (1) HUP0202515A3 (ru)
IL (1) IL148415A0 (ru)
LT (1) LT5001B (ru)
LV (1) LV12940B (ru)
MX (1) MXPA02002186A (ru)
NO (1) NO20020998L (ru)
NZ (1) NZ517470A (ru)
PE (1) PE20010579A1 (ru)
PL (1) PL353994A1 (ru)
SI (1) SI20853A (ru)
SK (1) SK2982002A3 (ru)
UA (1) UA77150C2 (ru)
WO (1) WO2001026603A2 (ru)
YU (1) YU13902A (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1525215T3 (da) * 2002-08-02 2007-01-15 Schering Ag Modulatorer for receptoren for progesteron med forhöjet anti-gonadotrop aktivitet til fertilitetskontrol hos kvinder og ved terapi til erstatning af hormoner
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
WO2004098517A2 (en) * 2003-05-02 2004-11-18 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
EP1773344A1 (en) * 2004-07-07 2007-04-18 Wyeth a Corporation of the State of Delaware Cyclic progestin regimens and kits
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
HRP20161437T1 (hr) * 2009-04-14 2017-02-10 Laboratoire Hra Pharma Postupak hitne kontracepcije
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
AU630334B2 (en) * 1987-09-24 1992-10-29 Jencap Research Ltd. Hormone preparations for hormone replacement therapy and contraceptive method
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4447714C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur Hormonsubstitutions-Therapie
ZA959008B (en) * 1994-10-24 1996-09-16 Schering Ag Competitive progesterone antagonists for demand-oriented female birth control
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
ATE213947T1 (de) * 1996-06-25 2002-03-15 Akzo Nobel Nv Progestogen-anti-progestogen therapien
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
AU4501800A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
BR0013711A (pt) 2002-05-07
BG106441A (bg) 2002-09-30
NO20020998L (no) 2002-03-14
WO2001026603A3 (en) 2002-01-17
LV12940B (en) 2003-06-20
CZ2002707A3 (cs) 2002-11-13
AU781835B2 (en) 2005-06-16
WO2001026603A2 (en) 2001-04-19
JP2003511399A (ja) 2003-03-25
PL353994A1 (en) 2003-12-15
EP1605949A2 (en) 2005-12-21
PE20010579A1 (es) 2001-06-04
CA2383650A1 (en) 2001-04-19
YU13902A (sh) 2006-01-16
KR20020038745A (ko) 2002-05-23
NO20020998D0 (no) 2002-02-28
CN1384748A (zh) 2002-12-11
CO5190694A1 (es) 2002-08-29
NZ517470A (en) 2004-03-26
MXPA02002186A (es) 2002-09-02
SI20853A (sl) 2002-10-31
AR025455A1 (es) 2002-11-27
LT5001B (lt) 2003-03-25
AU3215001A (en) 2001-04-23
SK2982002A3 (en) 2002-07-02
HRP20020265A2 (en) 2004-02-29
UA77150C2 (en) 2006-11-15
HUP0202515A2 (hu) 2002-12-28
LT2002035A (lt) 2002-10-25
EE200200103A (et) 2003-04-15
HUP0202515A3 (en) 2004-06-28
IL148415A0 (en) 2002-09-12
EA006805B1 (ru) 2006-04-28

Similar Documents

Publication Publication Date Title
WO1995011013A3 (de) Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen
AU3694901A (en) A parasiticidal formulation and a method of making this formulation
EA200000492A1 (ru) Пероральные контрацептивы, содержащие антиэстроген плюс прогестин
KR940005290A (ko) 생점착성 치료 조성물 및 사용방법
BR9714270A (pt) Composição lìquida de limpeza de pele
WO2002051363A3 (en) Absorbent articles with simplified compositions having good stability
BR0215380A (pt) Pó micronizado farmacêutico ou nutracêutico de liberação imediata e utilização do mesmo
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
UA37259C2 (ru) Активное вещество для получения лекарственных средств для лечения дисфункциональных маточных кровотечений
EA200200284A1 (ru) Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента женских контрацептивов
EA200100828A1 (ru) 16-гидроксиэстратриены в качестве эстрогенов избирательного действия
YU14002A (sh) Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja
BR0214332A (pt) Método para prover uma composição de base tópica para uso na preparação de uma composição cosmética, recipiente cosmético re-selável, e, composição anidra
EA200601089A1 (ru) Трансдермальная доставка гормонов без необходимости использования агентов, усиливающих проникновение
EP0247251B1 (en) Vaginal contraceptive
Bygdeman et al. Medical termination of early pregnancy: the Swedish experience
WO2003099322A3 (en) Il-11 derivatives and therapeutic uses thereof
EA200200285A1 (ru) Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента композиций для заместительной гормональной терапии (згт)
SE9201425D0 (sv) Method and means for preventing constriction of the pupil in the eye
JP4022675B2 (ja) 鎮痒剤組成物
SE8901149D0 (sv) Medel foer inducering respektive foerhindrande av pupillkonstriktion i oegat
AU9028098A (en) Combinations of endometrial sparing progestins and endometrial atrophizing progestins with estrogens, in oral contraception
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
BR0214334A (pt) Método para prover uma composição de base tópica para uso na preparação de uma composição cosmética, recipiente cosmético re-selável, e, composição anidra
WO1997033597A1 (en) An aphrodisiac for application to the sexual organs

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU